BAXTER HEALTHCARE CORP (United States) holds 3 active US FDA Type II Drug Master Files and 3 inactive, has DMF or CEP filings on record for 3 active ingredients and is linked to 8 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “BAXTER HEALTHCARE CORP: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/baxter-healthcare-corp

Overview

BAXTER HEALTHCARE CORP is an active pharmaceutical ingredient (API) supplier with 3 active FDA Type II Drug Master Files, covering CYCLOPHOSPHAMIDE, USP/EP; IFOSFAMIDE USP/EP; MESNA, USP/EP DRUG SUBSTANCE.

Core services & business areas

API ManufacturingPharmaceutical Manufacturing

Active ingredients with DMF or CEP filings

Substances for which BAXTER HEALTHCARE CORP holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

BAXTER HEALTHCARE CORP holds 3 active (6 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • MESNA, USP/EP DRUG SUBSTANCEActive2011-09-08
  • CYCLOPHOSPHAMIDE, USP/EPActive1979-06-11
  • IFOSFAMIDE USP/EPActive1979-04-24
  • MURINE MONOCLONAL ANTIBODIES (ANTI-CD8/CD4) TO HUMAN T-CELLSInactive2005-08-23
  • ANTI-PROTEIN C AFFINITY MATRIXInactive1990-12-21
  • FACILITIES IN MORTON GROVE, IL AND BRIDGEPORT, NJInactive1988-07-12

Registered manufacturing sites (8)

Physical sites registered with the US FDA and resolved to BAXTER HEALTHCARE CORP, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • warning_letter2026-09-29

    FDA Warning Letter (drug product)

  • 4832026-09-23

    Procedures for sterile drug products

  • 4832026-09-23

    Investigations of discrepancies, failures

  • 4832026-09-23

    Control procedures to monitor and validate performance

  • 4832026-09-23

    Procedures not in writing, fully followed

  • 4832026-09-23

    SOPs not followed / documented

  • recall — Class I2026-09-16

    Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class I2026-09-09

    Presence of particulate matter: Particulates identified as fiberglass

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class II2026-09-09

    CGMP Deviations

  • recall — Class I2026-08-19

    Presence of Particulate Matter

  • 4832026-04-02

    Investigations of discrepancies, failures

  • 4832026-04-02

    Written procedures not established/followed

  • 4832026-04-02

    Training--operations, GMPs, written procedures

  • 4832026-04-02

    Procedure Deviations Recorded and Justified

  • 4832026-04-02

    Equipment Design, Size and Location

  • 4832026-04-02

    Defined areas of adequate size for operations

  • 4832026-04-02

    Validation lacking for sterile drug products

  • 4832026-04-02

    Following/documenting laboratory controls

  • 4832026-04-02

    Acceptance/Rejection Levels

  • recall — Class II2026-02-04

    Presence of particulate matter: plastic particles from the bottle rim were observed floating into the solution

  • 4832025-11-25

    Computer control of master formula records

  • 4832025-11-25

    Sample identification and other information

  • 4832025-11-25

    Procedures not in writing, fully followed

  • 4832025-11-25

    Scientifically sound laboratory controls

  • 4832025-11-25

    Training , Education , Experience overall

  • 4832025-09-29

    Scientifically sound laboratory controls

  • 4832025-09-29

    Backup data not assured as exact and complete

  • 4832025-09-29

    Cleaning / Sanitizing / Maintenance

  • 4832025-09-29

    Buildings not maintained in good state of repair

  • 4832025-09-29

    Investigations of discrepancies, failures

  • recall — Class II2025-09-03

    Discoloration

  • 4832025-03-26

    Procedures not in writing, fully followed

  • recall — Class II2024-11-13

    Labeling: Missing Label

  • recall — Class I2024-09-11

    Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

For suppliers

Is this BAXTER HEALTHCARE CORP?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.